JP2006507329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507329A5 JP2006507329A5 JP2004552424A JP2004552424A JP2006507329A5 JP 2006507329 A5 JP2006507329 A5 JP 2006507329A5 JP 2004552424 A JP2004552424 A JP 2004552424A JP 2004552424 A JP2004552424 A JP 2004552424A JP 2006507329 A5 JP2006507329 A5 JP 2006507329A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- halo
- phenyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001257 hydrogen Substances 0.000 claims 64
- 229910052739 hydrogen Inorganic materials 0.000 claims 64
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 125000001475 halogen functional group Chemical group 0.000 claims 51
- 150000002431 hydrogen Chemical class 0.000 claims 49
- 125000001188 haloalkyl group Chemical group 0.000 claims 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims 39
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 27
- -1 nitro, cyano, phenyl Chemical group 0.000 claims 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 21
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 125000004043 oxo group Chemical group O=* 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 206010010904 Convulsion Diseases 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000007954 hypoxia Effects 0.000 claims 4
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 206010013663 drug dependence Diseases 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- DRPORMUHNHGFLD-UHFFFAOYSA-N 4-chloro-2-[(2-iodophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1I DRPORMUHNHGFLD-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 208000004404 Intractable Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000005809 status epilepticus Diseases 0.000 claims 2
- BIAYVBTUMYRJBI-UHFFFAOYSA-N 1-(3-bromophenyl)-3-[5-chloro-2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]urea Chemical compound C=1C=CC(Br)=CC=1NC(=O)NC1=CC(Cl)=CC=C1C1=NOC(=O)N1 BIAYVBTUMYRJBI-UHFFFAOYSA-N 0.000 claims 1
- JIMXLVJAMRAHOZ-UHFFFAOYSA-N 1-[5-chloro-2-(2h-tetrazol-5-yl)phenyl]-3-naphthalen-2-ylurea Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NC1=CC(Cl)=CC=C1C1=NN=NN1 JIMXLVJAMRAHOZ-UHFFFAOYSA-N 0.000 claims 1
- JHUBTWRPSAEQAH-UHFFFAOYSA-N 1-[5-chloro-2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea Chemical compound FC(F)(F)C1=CC=CC(NC(=O)NC=2C(=CC=C(Cl)C=2)C=2NC(=O)ON=2)=C1 JHUBTWRPSAEQAH-UHFFFAOYSA-N 0.000 claims 1
- VMKDUMUALKECDD-UHFFFAOYSA-N 1-[5-chloro-2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]-3-naphthalen-2-ylurea Chemical compound C=1C=C2C=CC=CC2=CC=1NC(=O)NC1=CC(Cl)=CC=C1C1=NOC(=O)N1 VMKDUMUALKECDD-UHFFFAOYSA-N 0.000 claims 1
- JRTRHAJORIWUJX-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-ylcarbamoylamino)-4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(OCO2)C2=C1 JRTRHAJORIWUJX-UHFFFAOYSA-N 0.000 claims 1
- SWXCGNGGTRXUTL-UHFFFAOYSA-N 2-[(2-bromophenyl)carbamoylamino]-4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1Br SWXCGNGGTRXUTL-UHFFFAOYSA-N 0.000 claims 1
- JHBDMFCBQQGZTP-UHFFFAOYSA-N 2-[(3-bromophenyl)carbamoylamino]-4-chloro-5-methylbenzenesulfonic acid Chemical compound C1=C(Cl)C(C)=CC(S(O)(=O)=O)=C1NC(=O)NC1=CC=CC(Br)=C1 JHBDMFCBQQGZTP-UHFFFAOYSA-N 0.000 claims 1
- FUZOGGHSNBXLIL-UHFFFAOYSA-N 2-[(3-bromophenyl)carbamoylamino]-4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(Br)=C1 FUZOGGHSNBXLIL-UHFFFAOYSA-N 0.000 claims 1
- LBWDNZCDWOZSOL-UHFFFAOYSA-N 2-[2-[(3-bromophenyl)carbamoylamino]-4-chlorophenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(Br)=C1 LBWDNZCDWOZSOL-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- XNDJMNYMZWBAKT-UHFFFAOYSA-N 4-chloro-2-(1h-indol-2-ylcarbamoylamino)-5-methylbenzenesulfonic acid Chemical compound C1=C(Cl)C(C)=CC(S(O)(=O)=O)=C1NC(=O)NC1=CC2=CC=CC=C2N1 XNDJMNYMZWBAKT-UHFFFAOYSA-N 0.000 claims 1
- PQNJQLMZJYDJCS-UHFFFAOYSA-N 4-chloro-2-(1h-indol-2-ylcarbamoylamino)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC2=CC=CC=C2N1 PQNJQLMZJYDJCS-UHFFFAOYSA-N 0.000 claims 1
- ODWUYZAAMNLBKT-UHFFFAOYSA-N 4-chloro-2-(naphthalen-2-ylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(C=CC=C2)C2=C1 ODWUYZAAMNLBKT-UHFFFAOYSA-N 0.000 claims 1
- KWZAOORTSIYEAN-UHFFFAOYSA-N 4-chloro-2-(phenylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1 KWZAOORTSIYEAN-UHFFFAOYSA-N 0.000 claims 1
- LYJNLSVTXUEARX-UHFFFAOYSA-N 4-chloro-2-(pyridin-2-ylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=N1 LYJNLSVTXUEARX-UHFFFAOYSA-N 0.000 claims 1
- NLJJXBBIDCIREM-UHFFFAOYSA-N 4-chloro-2-(thiophen-2-ylcarbamoylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CS1 NLJJXBBIDCIREM-UHFFFAOYSA-N 0.000 claims 1
- IVTCCQWGKNDDCB-UHFFFAOYSA-N 4-chloro-2-[(2-hydroxyphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1O IVTCCQWGKNDDCB-UHFFFAOYSA-N 0.000 claims 1
- VSZKUIZXGWUDLH-UHFFFAOYSA-N 4-chloro-2-[(2-methoxyphenyl)carbamoylamino]benzoic acid Chemical compound COC1=CC=CC=C1NC(=O)NC1=CC(Cl)=CC=C1C(O)=O VSZKUIZXGWUDLH-UHFFFAOYSA-N 0.000 claims 1
- DCLLIIGZJAINFF-UHFFFAOYSA-N 4-chloro-2-[(2-phenylphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1C1=CC=CC=C1 DCLLIIGZJAINFF-UHFFFAOYSA-N 0.000 claims 1
- PYDGXNVMBSNMMZ-UHFFFAOYSA-N 4-chloro-2-[(3-chlorophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(Cl)=C1 PYDGXNVMBSNMMZ-UHFFFAOYSA-N 0.000 claims 1
- YJXCIVXLYIAFFB-UHFFFAOYSA-N 4-chloro-2-[(3-hydroxyphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(O)=C1 YJXCIVXLYIAFFB-UHFFFAOYSA-N 0.000 claims 1
- HDVLBTNZJJUZTI-UHFFFAOYSA-N 4-chloro-2-[(3-iodophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(I)=C1 HDVLBTNZJJUZTI-UHFFFAOYSA-N 0.000 claims 1
- YYTGSSNODJDIJV-UHFFFAOYSA-N 4-chloro-2-[(3-phenylphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(C=2C=CC=CC=2)=C1 YYTGSSNODJDIJV-UHFFFAOYSA-N 0.000 claims 1
- MLGALOZSVFKMSG-UHFFFAOYSA-N 4-chloro-2-[(4-chlorophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(Cl)C=C1 MLGALOZSVFKMSG-UHFFFAOYSA-N 0.000 claims 1
- FWQMESGSECYCCQ-UHFFFAOYSA-N 4-chloro-2-[(4-fluorophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(F)C=C1 FWQMESGSECYCCQ-UHFFFAOYSA-N 0.000 claims 1
- QLLLLTXSZLAPFG-UHFFFAOYSA-N 4-chloro-2-[(4-hydroxyphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(O)C=C1 QLLLLTXSZLAPFG-UHFFFAOYSA-N 0.000 claims 1
- RGDBBRGPGZALER-UHFFFAOYSA-N 4-chloro-2-[(4-iodophenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(I)C=C1 RGDBBRGPGZALER-UHFFFAOYSA-N 0.000 claims 1
- IGVRXEWRIRSEMV-UHFFFAOYSA-N 4-chloro-2-[(4-methoxyphenyl)carbamoylamino]benzoic acid Chemical compound C1=CC(OC)=CC=C1NC(=O)NC1=CC(Cl)=CC=C1C(O)=O IGVRXEWRIRSEMV-UHFFFAOYSA-N 0.000 claims 1
- MHKORSIIJIQRMD-UHFFFAOYSA-N 4-chloro-2-[(4-phenylphenyl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(C=2C=CC=CC=2)C=C1 MHKORSIIJIQRMD-UHFFFAOYSA-N 0.000 claims 1
- PBNRVTPDAJAJOD-UHFFFAOYSA-N 4-chloro-2-[(9-oxofluoren-3-yl)carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(C(=O)C=2C3=CC=CC=2)C3=C1 PBNRVTPDAJAJOD-UHFFFAOYSA-N 0.000 claims 1
- PHAGATSOEHSZNZ-UHFFFAOYSA-N 4-chloro-2-[[2-(trifluoromethyl)phenyl]carbamoylamino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC=C1C(F)(F)F PHAGATSOEHSZNZ-UHFFFAOYSA-N 0.000 claims 1
- KBKIYZZQLOFTDK-UHFFFAOYSA-N 4-chloro-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 KBKIYZZQLOFTDK-UHFFFAOYSA-N 0.000 claims 1
- GNCZTZCPXFDPLI-UHFFFAOYSA-N 4-chloro-2-[[oxo-[3-(trifluoromethyl)anilino]methyl]amino]benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 GNCZTZCPXFDPLI-UHFFFAOYSA-N 0.000 claims 1
- UAJJKABSBNCYAN-UHFFFAOYSA-N 4-chloro-5-methyl-2-(naphthalen-2-ylcarbamoylamino)benzenesulfonic acid Chemical compound C1=C(Cl)C(C)=CC(S(O)(=O)=O)=C1NC(=O)NC1=CC=C(C=CC=C2)C2=C1 UAJJKABSBNCYAN-UHFFFAOYSA-N 0.000 claims 1
- LLLKNTGMZQZAIH-UHFFFAOYSA-N 4-chloro-5-methyl-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzenesulfonic acid Chemical compound C1=C(Cl)C(C)=CC(S(O)(=O)=O)=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 LLLKNTGMZQZAIH-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- YJLYKRYWHIFVSR-UHFFFAOYSA-N 6-chloro-n-naphthalen-2-yl-3-oxo-2h-indazole-1-carboxamide Chemical compound C12=CC(Cl)=CC=C2C(O)=NN1C(=O)NC1=CC=C(C=CC=C2)C2=C1 YJLYKRYWHIFVSR-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000002381 Brain Hypoxia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010051290 Central nervous system lesion Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010013647 Drowning Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 108010009117 Gluk1 kainate receptor Proteins 0.000 claims 1
- 206010019005 Haemorrhagic cerebral infarction Diseases 0.000 claims 1
- 208000027109 Headache disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010038669 Respiratory arrest Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical class 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003179 convulsant agent Substances 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000002461 excitatory amino acid Effects 0.000 claims 1
- 239000003257 excitatory amino acid Substances 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- XQJXNILPLUCHQG-UHFFFAOYSA-N n-phenyl-1h-indazole-3-carboxamide Chemical class N=1NC2=CC=CC=C2C=1C(=O)NC1=CC=CC=C1 XQJXNILPLUCHQG-UHFFFAOYSA-N 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000003961 neuronal insult Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- RKRLQDJTVWZXMM-UHFFFAOYSA-N CC(N1)=NOC1=O Chemical compound CC(N1)=NOC1=O RKRLQDJTVWZXMM-UHFFFAOYSA-N 0.000 description 1
- RDBWPJMZIPZQKR-UHFFFAOYSA-N CC1=NN(C)NN1 Chemical compound CC1=NN(C)NN1 RDBWPJMZIPZQKR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200201803 | 2002-11-21 | ||
| PCT/DK2003/000768 WO2004046090A2 (en) | 2002-11-21 | 2003-11-10 | Aryl ureido derivatives and their medical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006507329A JP2006507329A (ja) | 2006-03-02 |
| JP2006507329A5 true JP2006507329A5 (enExample) | 2007-01-25 |
Family
ID=32319497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004552424A Pending JP2006507329A (ja) | 2002-11-21 | 2003-11-10 | 新規アリールウレイド安息香酸誘導体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7521480B2 (enExample) |
| EP (1) | EP1565429B1 (enExample) |
| JP (1) | JP2006507329A (enExample) |
| CN (1) | CN1714076A (enExample) |
| AT (1) | ATE431335T1 (enExample) |
| AU (1) | AU2003280308A1 (enExample) |
| CA (1) | CA2502705A1 (enExample) |
| DE (1) | DE60327652D1 (enExample) |
| ES (1) | ES2327834T3 (enExample) |
| MX (1) | MXPA05005409A (enExample) |
| NZ (1) | NZ539499A (enExample) |
| PT (1) | PT1565429E (enExample) |
| WO (1) | WO2004046090A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004005172A1 (de) | 2004-02-02 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| CN101098852A (zh) * | 2004-11-09 | 2008-01-02 | 史密丝克莱恩比彻姆公司 | 糖原磷酸化酶抑制剂化合物和其药物组合物 |
| FR2878522B1 (fr) * | 2004-12-01 | 2008-04-18 | Merck Sante Soc Par Actions Si | Nouveaux inhibiteurs specifiques de la caspas-10 |
| CN101287456A (zh) * | 2004-12-17 | 2008-10-15 | 神经研究公司 | 用作钾通道激活剂的二苯基脲衍生物 |
| AU2006206611A1 (en) | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | 2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders |
| EP1899299B1 (en) | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| ES2360818T3 (es) | 2005-06-27 | 2011-06-09 | Bristol-Myers Squibb Company | Miméticos de urea lineal antagonistas del receptor p2y, útiles en el tratamiento de afecciones trombóticas. |
| US7714002B2 (en) | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| MX2007016501A (es) | 2005-06-27 | 2008-03-06 | Squibb Bristol Myers Co | Antagonistas heterociclicos n-enlazados del receptor de p2y1, utiles en el tratamiento de condiciones tromboticas. |
| WO2007044724A2 (en) * | 2005-10-06 | 2007-04-19 | Exelixis, Inc. | Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3 |
| WO2007104719A1 (en) * | 2006-03-14 | 2007-09-20 | Neurosearch A/S | Diphenylurea derivatives and their use as chloride channel blockers or bkca channel modulators |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| DE102007012908A1 (de) | 2007-03-19 | 2008-09-25 | Momentive Performance Materials Gmbh | Neue Polyamid-Polysiloxan-Verbindungen |
| AU2008309003A1 (en) * | 2007-09-28 | 2009-04-09 | Glaxosmithkline Llc | Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof |
| US20100292283A1 (en) * | 2007-11-28 | 2010-11-18 | Antonio Nardi | Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators |
| WO2011053468A1 (en) * | 2009-10-30 | 2011-05-05 | Sanofi-Aventis | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
| US10899702B2 (en) * | 2015-02-07 | 2021-01-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | HTRPVI chemical agents |
| JP7092356B2 (ja) * | 2016-06-22 | 2022-06-28 | フーダン ユニヴァーシティ | ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用 |
| CN106008371A (zh) * | 2016-06-24 | 2016-10-12 | 谢阳 | 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用 |
| CN106946786A (zh) * | 2017-04-11 | 2017-07-14 | 白银澐新生物科技有限公司 | 一种1‑苄基‑3‑羟基‑1h‑3‑吲唑钠盐的制备方法 |
| CN111116420B (zh) * | 2019-12-31 | 2022-01-14 | 浙江工业大学 | 一种对称脲类化合物的制备方法 |
| CN114539080A (zh) * | 2022-03-02 | 2022-05-27 | 八叶草健康产业研究院(厦门)有限公司 | 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH220682A (de) * | 1940-02-05 | 1942-04-30 | Geigy Ag J R | Verfahren zum Schützen von Pelzen, Federn, Haaren, fibrösen Materialien und andern Waren gegen Schädlinge. |
| GB709455A (en) | 1950-12-26 | 1954-05-26 | Variapat Ag | Water-soluble asymmetric ureas and thioureas and a process for their production |
| US2722544A (en) | 1950-12-26 | 1955-11-01 | Variapat Ag | Trifluoromethyl halogenated diphenylcarbamide sulfonic acids and their preparation |
| GB828231A (en) * | 1955-10-20 | 1960-02-17 | Geigy Ag J R | Improvements relating to insecticidal compounds and their use |
| GB1055786A (en) * | 1963-07-12 | 1967-01-18 | Ici Ltd | Urea derivatives |
| US3332981A (en) * | 1964-09-14 | 1967-07-25 | Gen Aniline & Film Corp | Urea stilbene brighteners |
| GB1210596A (en) * | 1967-04-06 | 1970-10-28 | Armour Grocery Products Compan | Antiseptic compositions |
| JPS5936614B2 (ja) * | 1973-03-09 | 1984-09-05 | フアイザ− インコ−ポレ−テツド | 安息香酸誘導体およびそれらの塩の製造方法 |
| DE2315302A1 (de) * | 1973-03-27 | 1974-10-17 | Bayer Ag | Verfahren zur herstellung von nitrochinazolindionen |
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| GB8429739D0 (en) * | 1984-11-24 | 1985-01-03 | Fbc Ltd | Fungicides |
| GB8820129D0 (en) * | 1988-08-24 | 1988-09-28 | Schering Agrochemicals Ltd | Fungicides |
| DK41193D0 (da) | 1993-04-07 | 1993-04-07 | Neurosearch As | Ionkanalaabnere |
| US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
| CA2154323C (en) * | 1994-07-21 | 2001-03-27 | Tomoaki Nagai | Aminobenzenesulfonamide derivative and recording medium using the same |
| CA2161376C (en) * | 1994-10-27 | 2005-01-11 | Toshiaki Minami | Reversible multi-color thermal recording medium |
| EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| US5985872A (en) * | 1995-05-24 | 1999-11-16 | G.D. Searle & Co. | 2-amino-benzoxazinones for the treatment of viral infections |
| US5811369A (en) * | 1995-12-01 | 1998-09-22 | Nippon Paper Industries Co., Ltd. | Thermal recording medium |
| DE69612358T2 (de) * | 1995-12-08 | 2001-07-12 | Nippon Paper Industries Co. Ltd., Tokio/Tokyo | Wärmeempfindliches Aufzeichnungsmedium |
| US6262113B1 (en) * | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| EP0906273B1 (en) | 1996-05-24 | 2002-10-16 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
| JP2000510862A (ja) | 1996-05-24 | 2000-08-22 | ニューロサーチ・アクティーゼルスカブ | クロライドチャンネル遮断剤として有用なフエニル誘導体 |
| SK282818B6 (sk) | 1997-04-22 | 2002-12-03 | Neurosearch A/S | Substituované fenylderiváty, ich príprava, použitie a farmaceutický prípravok |
| US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| WO1999038846A1 (en) | 1998-01-30 | 1999-08-05 | Procept, Inc. | Immunosuppressive agents |
| PL198852B1 (pl) * | 1998-10-22 | 2008-07-31 | Neurosearch As | Podstawione pochodne fenylu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie |
| SE9903894D0 (sv) * | 1999-10-28 | 1999-10-28 | New Pharma Research Ab | Novel compounds |
| WO2002039987A2 (en) * | 2000-11-14 | 2002-05-23 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| JP2004520396A (ja) | 2001-02-15 | 2004-07-08 | ニューロサーチ、アクティーゼルスカブ | 過剰な又は不十分な細胞死によって特徴づけられる疾患の治療 |
| WO2002070467A1 (en) | 2001-02-26 | 2002-09-12 | 4Sc Ag | Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments |
| WO2003000245A1 (en) | 2001-06-22 | 2003-01-03 | Poseidon Pharmaceuticals A/S | Compounds for use in disorders associated with mast cell or basophil activity |
| DE10131133A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Pyridazinone |
| US7211575B2 (en) | 2001-09-13 | 2007-05-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
-
2003
- 2003-11-10 DE DE60327652T patent/DE60327652D1/de not_active Expired - Lifetime
- 2003-11-10 JP JP2004552424A patent/JP2006507329A/ja active Pending
- 2003-11-10 PT PT03770917T patent/PT1565429E/pt unknown
- 2003-11-10 CA CA002502705A patent/CA2502705A1/en not_active Abandoned
- 2003-11-10 ES ES03770917T patent/ES2327834T3/es not_active Expired - Lifetime
- 2003-11-10 WO PCT/DK2003/000768 patent/WO2004046090A2/en not_active Ceased
- 2003-11-10 CN CNA200380103761XA patent/CN1714076A/zh active Pending
- 2003-11-10 US US10/535,683 patent/US7521480B2/en not_active Expired - Fee Related
- 2003-11-10 EP EP03770917A patent/EP1565429B1/en not_active Expired - Lifetime
- 2003-11-10 AT AT03770917T patent/ATE431335T1/de not_active IP Right Cessation
- 2003-11-10 AU AU2003280308A patent/AU2003280308A1/en not_active Abandoned
- 2003-11-10 MX MXPA05005409A patent/MXPA05005409A/es unknown
- 2003-11-10 NZ NZ539499A patent/NZ539499A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507329A5 (enExample) | ||
| JP2020055824A (ja) | 中枢神経系疾患および障害の治療に有効な新規化合物 | |
| TW555735B (en) | Diarylpropylamines, methods for their preparation and pharmaceutical compositions containing them | |
| US20120225845A1 (en) | Compounds for diseases and disorders | |
| US20170313719A1 (en) | Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto | |
| JP5342451B2 (ja) | Ｐｄｅ４阻害剤として有用な置換アセトフェノン | |
| JP2011528372A (ja) | α７ニコチン性アセチルコリンレセプターインヒビター | |
| FI78691B (fi) | Foerfarande foer framstaellning av i position 3-substituerade pyridazinderivat, vilka inverkar pao det centrala nervsystemet. | |
| JP2006022108A5 (enExample) | ||
| JP2012526082A5 (enExample) | ||
| JP2006507329A (ja) | 新規アリールウレイド安息香酸誘導体及びその使用 | |
| CN101679287A (zh) | 烟碱型乙酰胆碱受体调节剂 | |
| CN106536498A (zh) | 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺 | |
| TW200836739A (en) | Substituted 2, 5-dihydro-3H-pyrazolo[4, 3-c] pyridazin-3-one derivatives, preparation thereof and therapeutic use thereof | |
| EP2468732B1 (en) | 1H-Quinazoline-2,4-diones | |
| US20080249135A1 (en) | Compounds for alzheimer's disease | |
| HUP9903797A2 (hu) | Benzofurán-karboxamidok és -szulfonamidok, alkalmazásuk gyógyszerkészítmények előállítására és ezek a gyógyszerkészítmények | |
| RU2655919C2 (ru) | Производные аминоциклобутана, способ их получения и их применение в качестве лекарственных средств | |
| JP2010505867A (ja) | ピラゾール化合物 | |
| JP2008508247A5 (enExample) | ||
| JP2004501136A (ja) | Ｎｍｄａ受容体の選択的拮抗薬としてのアミジン誘導体 | |
| JP2006503062A5 (enExample) | ||
| JP2008542365A5 (enExample) | ||
| JP2021529813A (ja) | チアジアジン誘導体 | |
| JPH02131452A (ja) | 抗痙攣用または神経保護用医薬 |